Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.89
SGYP's Cash to Debt is ranked lower than
64% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. SGYP: 0.89 )
Ranked among companies with meaningful Cash to Debt only.
SGYP' s 10-Year Cash to Debt Range
Min: 0.13  Med: 10000.00 Max: No Debt
Current: 0.89
F-Score: 3
Z-Score: -0.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -591.97
SGYP's ROE (%) is ranked lower than
100% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. SGYP: -591.97 )
Ranked among companies with meaningful ROE (%) only.
SGYP' s 10-Year ROE (%) Range
Min: -899.32  Med: -319.10 Max: -154.96
Current: -591.97
-899.32
-154.96
ROA (%) -92.22
SGYP's ROA (%) is ranked lower than
97% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGYP: -92.22 )
Ranked among companies with meaningful ROA (%) only.
SGYP' s 10-Year ROA (%) Range
Min: -6858.53  Med: -154.23 Max: -66.95
Current: -92.22
-6858.53
-66.95
ROC (Joel Greenblatt) (%) -16486.53
SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. SGYP: -16486.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGYP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -423053.33  Med: -169122.22 Max: -15143.46
Current: -16486.53
-423053.33
-15143.46
EBITDA Growth (3Y)(%) 48.90
SGYP's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. SGYP: 48.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGYP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 35.90 Max: 122.4
Current: 48.9
0
122.4
EPS Growth (3Y)(%) 50.40
SGYP's EPS Growth (3Y)(%) is ranked higher than
92% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SGYP: 50.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGYP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 35.90 Max: 122.4
Current: 50.4
0
122.4
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SGYP Guru Trades in Q1 2014

Jim Simons 197,390 sh (-5.37%)
» More
Q2 2014

SGYP Guru Trades in Q2 2014

Paul Singer 450,400 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

SGYP Guru Trades in Q4 2014

Jim Simons 162,095 sh (New)
» More
Q1 2015

SGYP Guru Trades in Q1 2015

Paul Tudor Jones 11,517 sh (New)
John Paulson 2,095,600 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 9.53
SGYP's Current Ratio is ranked higher than
89% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. SGYP: 9.53 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s 10-Year Current Ratio Range
Min: 0.04  Med: 1.76 Max: 11.88
Current: 9.53
0.04
11.88
Quick Ratio 9.53
SGYP's Quick Ratio is ranked higher than
90% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SGYP: 9.53 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s 10-Year Quick Ratio Range
Min: 0.04  Med: 1.76 Max: 11.88
Current: 9.53
0.04
11.88

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -11.89
SGYP's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SGYP: -11.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGYP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -36.2  Med: 0.00 Max: 0
Current: -11.89
-36.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 08 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer Jul 08 2015
Trending Now: Synergy Pharmaceuticals Jul 06 2015
10 Best Biotech Stocks in the NASDAQ Jul 01 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 01 2015
6 Analyst Stocks Predicted to Double Jul 01 2015
Synergy Pharmaceuticals Appoints Timothy Callahan and Richard Daly to Board of Directors Jul 01 2015
Synergy Pharmaceuticals to Present at the Cantor Fitzgerald Healthcare Conference Jun 30 2015
Can The Uptrend Continue for Synergy Pharmaceuticals (SGYP)? - Tale of the Tape Jun 25 2015
Synergy Pharmaceuticals' Plecanatide in 2nd IBS-C study - Analyst Blog Jun 24 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 23 2015
Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with... Jun 23 2015
5 Analyst Stocks With 50% to 100% Upside Potential Jun 20 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Jun 19 2015
Synergy Pharmaceuticals Soars on Constipation Drug Data - Analyst Blog Jun 18 2015
Why This Analyst Sees Synergy Pharma Still Doubling Even After Huge Gains Jun 18 2015
Synergy Pharmaceuticals (SGYP) Stock Price Target Hiked at Cantor Fitzgerald Jun 18 2015
June 18 Premarket Briefing: 10 Things You Should Know Jun 18 2015
Ironwood Pharmaceuticals Whittled Down Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK